{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"142.1","upperLimit":"204.9","value":"170.1"},{"groupId":"OG001","lowerLimit":"104.1","upperLimit":"176.9","value":"136.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"176"}],"units":"Participants"}],"description":"Overall survival was calculated as the time from randomization to death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"CC-5013 (lenalidomide) plus oral high-dose dexamethasone","id":"OG000","title":"CC-5013/Dex"},{"description":"Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone","id":"OG001","title":"Placebo/Dex"}],"paramType":"MEDIAN","populationDescription":"Analysis conducted on the Intent-To-Treat (ITT) Population. The ITT Population was defined as all subjects randomized.","reportingStatus":"POSTED","timeFrame":"170 weeks (median overall survival of CC-5013/Dex treatment group)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Weeks"}